Becton, Dickinson and Company (BIT:1BDX)
Italy
· Delayed Price · Currency is EUR 166.90
+14.45 (9.48%)
At close: Aug 14, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is October - September.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2012 - 2019 |
| Medication Delivery Solutions | 4.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery Solutions Growth | 3.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Systems | 2.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Systems Growth | 2.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biosciences | 1.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biosciences Growth | -3.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -67.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Management Solutions | 3.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Management Solutions Growth | 9.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgery | 1.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgery Growth | 3.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Peripheral Intervention | 1.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Peripheral Intervention Growth | 2.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Critical Care | 1.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Critical Care Growth | 5.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical | 10.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Growth | 13.77% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences | 5.19B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Growth | -0.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional | 4.98B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Growth | 3.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -67.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is October - September.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2012 - 2019 |
| Other | -2.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Operating Income | 2.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Operating Income Growth | 27.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income | 1.60B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income Growth | -1.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -2.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Operating Income | 1.42B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Interventional Operating Income Growth | 14.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|